Key result
RNase III cleavage specificity is determined by the distance from the end of continuous pairing and by nucleotide sequence features within the region of pairing.
Population
lambda cII mRNA and lambda OOP antisense RNA structures
Design
Preclinical
Authors
Loading...
Preclinical RNase III rules should not guide therapy; leaves open validation for human RNA applications.
RNase III cleavage specificity is determined by both the distance from the end of continuous RNA pairing and specific nucleotide sequence features.
Krinke et al. (1990) studied this question. RNase III was evaluated on Cleavage specificity and sites in lambda cII mRNA. RNase III cleavage specificity is determined by the distance from the end of continuous pairing and by nucleotide sequence features within the region of pairing.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: